Clinical trials · Maryland
Metastatic Prostate Adenocarcinoma clinical trials in Maryland
We’re tracking 35 recruiting metastatic prostate adenocarcinoma studies with a site in Maryland — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Baltimore, MarylandAges 18 years+ - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
Baltimore, MarylandAges 18 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Baltimore, MarylandAges 18 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Bethesda, MarylandAges 18 years+ - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Baltimore, MarylandAges 18 years+ - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Towson, MarylandAges 18–130 - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Baltimore, MarylandAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Baltimore, MarylandAges 18–100 - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Baltimore, MarylandAges 18 years+ - NCT06165302Recruiting
Exercise study for men with advanced prostate cancer
This trial tests whether a structured exercise program can help men with metastatic prostate cancer who are on hormone therapy. It looks at changes in cancer cells and overall well-being.
Baltimore, MarylandAges 18–80 - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Baltimore, MarylandAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Baltimore, MarylandAges 18 years+ - NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
Baltimore, MarylandAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Baltimore, MarylandAges 18 years+ - NCT06826924Recruiting
Fasting or ketones for prostate cancer
This trial tests whether a 7-day water-only fast or taking ketone supplements can help treat prostate cancer. You would have a biopsy before and after to see how the tumor responds.
Baltimore, MarylandAges 18 years+ - NCT06257693RecruitingPhase 1
Prostate cancer implant trial before prostate removal surgery
This trial tests a new enzalutamide implant (Enolen) placed in the prostate before surgery to see if it helps treat early prostate cancer. It is for men who are already planning to have their prostate removed.
Baltimore, MarylandAges 21 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Baltimore, MarylandAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Baltimore, MarylandAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Baltimore, MarylandAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Baltimore, MarylandAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Baltimore, MarylandAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Baltimore, MarylandAges 18 years+
Metastatic Prostate Adenocarcinoma trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting metastatic prostate adenocarcinoma studies listed above.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 8 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 6 studies
- Johns Hopkins University · 5 studies
- Chesapeake Urology Research Associates · 3 studies
- Johns Hopkins Hospital · 3 studies
- James M Stockman Cancer Institute · 2 studies
- National Institutes of Health Clinical Center · 2 studies
- University of Maryland Baltimore Washington Medical Center · 2 studies
What taking part in a metastatic prostate adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Prostate Adenocarcinoma trials in other states
Common questions
- Are there metastatic prostate adenocarcinoma clinical trials in Maryland?
- Yes. We're currently tracking 35 recruiting metastatic prostate adenocarcinoma studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate adenocarcinoma study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate adenocarcinoma studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.